Crizotinib and erlotinib (an EGFR inhibitor) showed synergistic effects in orthotopic tumor model mice [97], and it is tempting to propose the combination of Crizotinib and erlotinib in patients with HGFR+/EGFR+ GBM. Here, MET is linked to glioblastoma.